Heptares Therapeutics
Andrew Brimblecombe has over 20 years of work experience. Andrew began their career as an R&D Chemist at Dow Corning from 1996 to 2001. Andrew then worked as an Auditor at Deloitte & Touche LLP from 2002 to 2005. From 2005 to 2008, they served as a Financial Accountant at Enviros Consulting Ltd. Andrew then worked as a Group Accountant at Huntingdon Life Sciences from 2008 to 2013. Currently, they are the Head of Finance at Sosei Heptares, a position they have held since 2013.
Andrew Brimblecombe's education history is as follows:
From 1982 to 1989, Andrew attended Ivybridge Community College for their secondary education.
From 1989 to 1993, they pursued a Bachelor of Science (BSc) degree in Chemistry at the University of Southampton.
Subsequently, from 1993 to 1996, Andrew continued their studies at the University of Southampton, earning a Doctor of Philosophy (PhD) degree in Chemistry.
Later on, from 2002 to 2005, they attended the Institute of Chartered Accountants in England and Wales (ICAEW) to pursue a certification in Accountancy (ACA).
No further information regarding their specific field of study during their ACA certification is provided.
This person is not in any teams
Heptares Therapeutics
Heptares Therapeutics is a drug discovery company focused on novel small-molecule drugs targeting G-protein-coupled receptors (GPCRs), the largest family of druggable targets.The Company has developed a unique, transformational and proprietary technology for making purified, stabilised and functional GPCRs (known as StaRs, StabilisedReceptors), overcoming a major limiting factor to the development of new drugs targeting this group.